Skip to main content

Table 1 Baseline information of the patients

From: Efficacy of wIRA in the treatment of sacroiliitis in male patients with ankylosing spondylitis and its effect on serum VEGF levels

  Group A Group B t/x2-statistic P value
Age (years) 32.05 ± 10.96 32.60 ± 13.01 − 0.145 0.886
Disease course (years) 6.92 ± 3.21 6.40 ± 2.70 0.554 0.583
HLA-27 positive rates 95% (57/60) 100% (60/60) 1.026 0.311
CRP (mg/L) 30.21 ± 6.98 30.04 ± 8.33 0.070 0.945
VEGF (pg/ml) 180.22 ± 18.51 182.87 ± 23.31 − 0.399 0.692
BASDAI scores (0–10) 8.30 ± 0.78 8.43 ± 0.80 − 0.522 0.604
Pain VAS scores (0–10) 8.90 ± 0.52 8.80 ± 0.54 0.597 0.554
Morning stiffness-VAS scores (0–10) 8.79 ± 0.55 8.77 ± 0.53 0.145 0.885
RI 0.52 ± 0.04 0.54 ± 0.06 − 1.17 0.249
  1. HLA-27 human leukocyte antigen B27, CRP C-reactive protein, VEGF vascular endothelial growth factor, BASDAI bath ankylosing spondylitis disease activity index, RI resistance index, VAS visual analogue scale